Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIMEPAN study of timing of systemic treatment in asymptomatic metastatic pancreatic cancer
2023-509465-20-00Phase 3Authorised
- Sponsor
- Amsterdam University Medical Center
- Start
- Oct 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of nab-paclitaxel, gemcitabine, oxaliplatin, irinotecan and fluorouracil in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Quality Adjusted Overall Survival. Planned start Oct 2024; status: authorised.
02
Drugs
nab-paclitaxelgemcitabineoxaliplatinirinotecanfluorouracil
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2023-509465-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509465-20-00.